Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - ID Biomedical Corporation (NasdaqNM:IDBE)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Msgs | Reports
Location
1510-800 West Pender Street
British Columbia
Vancouver, V6C 2V6, Canada
Phone: (604) 431-9314
Fax: (604) 431-9378
Email: info@idbiomed.com
Employees (last reported count): 30
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 6%
·Institutional: 4% (4% of float)
(16 institutions)
·Net Inst. Buying: 178.0K shares (+15.06%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
ID Biomedical Corporation is a biotechnology company involved in gene-based disease identification and sub-unit vaccines. The Company is developing gene-based disease identification assays (tests for a particular substance) using its proprietary gene-detection system known as Cycling Probe Technology (CPT). Using CPT, the Company is developing a gene-based format under the trade name Velogene. The Company's first product on the market is the Velogene Rapid MRSA Identification Assay for methicillin-resistant Staphyloccus aureus (MRSA). A second product candidate, the Velogene Rapid VRE Identification Assay for Vancomycin-resistant enterococcis is currently in pre-clinical development. Each assay uses CPT to detect the genes believed to be responsible for antibiotic resistance in these organisms. The Company has three subsidiaries, ID Vaccine Corporation, ID Biomedical, Inc. and ID Financial Corporation.
More from Market Guide: Expanded Business Description

Financial Summary
IDBE is engaged in the development of sub-unit vaccines against infectious diseases and rapid gene-based disease identification. For the three months ended 3/31/01, revenues totaled C$1.2 million, up from C$180 thousand. Net loss fell 42% to C$1 million. Revenues reflect increased licensing payments received and earned interest and other income. Lower loss reflect improved margins and lower interest balances on convertible debentures and capital leasing arrangements.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 1,327; after tax earnings were -2,323. (Preliminary; reported in thousands of Canadian Dollars.)

More from Market Guide: Significant Developments

Officers
FY1999 Pay

Richard Bastiani
Chairman
--  
Anthony Holler
CEO, Director
$160K
Todd Patrick
Pres, COO
146K
Robert Bryan, Ph.D.
VP- R&D
111K
Deborah Bowers
Sec.
--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:IDBEAs of 31-Aug-2001
Price and Volume
52-Week Low
on 5-Apr-2001
$2.375
Recent Price$2.95 
52-Week High
on 5-Sep-2000
$8.188
Beta0.45 
Daily Volume (3-month avg)40.0K
Daily Volume (10-day avg)34.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-61.5%
52-Week Change
relative to S&P500
-48.3%
Share-Related Items
Market Capitalization$76.7M
Shares Outstanding26.0M
Float24.4M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 8-Aug-1995
Per-Share Data
Book Value (mrq*)$1.05 
Earnings (ttm)$0.05 
Earnings (mrq)-$0.05 
Sales (ttm)$0.29 
Cash (mrq*)$0.88 
Valuation Ratios
Price/Book (mrq*)2.82 
Price/Earnings (ttm)61.46 
Price/Sales (ttm)10.19 
Income Statements
Sales (ttm)$7.65M
EBITDA (ttm*)$4.42M
Income available to common (ttm)$781.0K
Profitability
Profit Margin (ttm)9.5%
Operating Margin (ttm)36.3%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)2.37%
Return on Equity (ttm)3.12%
Financial Strength
Current Ratio (mrq*)11.59 
Debt/Equity (mrq*)0.01 
Total Cash (mrq)$0 
Short Interest
As of 8-Aug-2001
Shares Short1,000 
Percent of Float0.0%
Shares Short
(Prior Month)
1,000 
Short Ratio0.03 
Daily Volume36.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001);   dollar amounts based on an exchange rate of 1.55 Canadian Dollars/US Dollar

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.